This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

This study has been completed.
Aspreva Pharmaceuticals
Information provided by:
Hoffmann-La Roche Identifier:
First received: December 5, 2006
Last updated: May 22, 2008
Last verified: May 2008
This 2 arm study will provide optional continuation of double-blind treatment with CellCept or placebo, in patients with myasthenia gravis who have achieved good symptom control in study WX17798. Patients who have completed 36 weeks of treatment in study WX17798, with stable prednisone dosing for the last 4 weeks, can continue on blinded treatment with CellCept (1g bid) or placebo until the database for WX17798 is locked and unblinded. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Condition Intervention Phase
Myasthenia Gravis Generalised Drug: mycophenolate mofetil [CellCept] Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind Study to Evaluate the Safety of Continued Treatment With CellCept in Patients With Well-Controlled Myasthenia Gravis Receiving a Stable Dose of Prednisone

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • AEs, laboratory parameters, vital signs. [ Time Frame: Throughout study ]

Estimated Enrollment: 136
Study Start Date: June 2004
Study Completion Date: September 2007
Arms Assigned Interventions
Experimental: 1 Drug: mycophenolate mofetil [CellCept]
1g po bid
Placebo Comparator: 2 Drug: Placebo
po bid


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • subjects who have completed 36 weeks of treatment in study WX17798, and who have demonstrated good symptom control with a stable prednisone dose for the final 4 weeks of that study.

Exclusion Criteria:

  • regularly scheduled plasma exchange or intravenous immunoglobulin treatment;
  • medical condition, adverse event or intolerance of double-blind treatment which would preclude continuation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00408213

United States, Arizona
Sun City, Arizona, United States, 85351
United States, California
Sacramento, California, United States, 95817
United States, Pennsylvania
Upland, Pennsylvania, United States, 19013
Former Serbia and Montenegro
Belgrade, Former Serbia and Montenegro, 11000
Bordeaux, France
Nice, France
München, Germany, 81675
Regensburg, Germany, 93053
Milano, Italy, 20133
Roma, Italy, 185
Kharkov, Ukraine, 61068
Kiev, Ukraine
Zaporozhye, Ukraine
United Kingdom
Liverpool, United Kingdom, L9 1AE
Oxford, United Kingdom, OX2 6HE
Salford, United Kingdom, M6 8HD
Sponsors and Collaborators
Hoffmann-La Roche
Aspreva Pharmaceuticals
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Clinical Trials, Study Director, Hoffmann-La Roche Identifier: NCT00408213     History of Changes
Obsolete Identifiers: NCT00231088
Other Study ID Numbers: WX18411
Study First Received: December 5, 2006
Last Updated: May 22, 2008

Additional relevant MeSH terms:
Myasthenia Gravis
Muscle Weakness
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathologic Processes
Signs and Symptoms
Autoimmune Diseases of the Nervous System
Neuromuscular Junction Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases
Mycophenolate mofetil
Mycophenolic Acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on September 21, 2017